Vancouver, Canada -- January 8, 2018 -- / D.M.O. Newswire / -- Anandia Laboratories Inc. (“Anandia Labs” or the “Company”), a leading Canadian cannabis biotechnology and testing company, announced that it has successfully completed its first export (the “Export”) of Canadian cannabis oil for use in Australia. The Export was conducted on behalf of one of the Company’s clients, a Canadian-based licensed cannabis producer, to facilitate a clinical trial program. Anandia Labs is one of only 33 entities with a Health Canada Dealers Licence (“Dealers Licence”) that permits activities with cannabis, enabling the Company to export cannabis products internationally and import cannabis products into Canada.
“Demand for Canadian medical cannabis is growing internationally, given the stringent quality control measures stipulated by Canadian regulations and the resulting quality of the product,” said Dr. Jonathan Page, President and CEO of Anandia Labs. “Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”) are rapidly becoming the international gold standard for medical cannabis production. This positions Licensed Dealers such as Anandia Labs as the go-to global players in providing certified cannabis products and disease-free genetic propagative material to licenced cannabis producers in Canada and worldwide. By providing Canadian-leading testing, genetics and extraction services, as well as acting as a conduit for the import and export of certified cannabis products, we are actively assisting our clients to develop their product pipelines and grow their businesses in a rapidly growing global industry.”
Anandia Labs’ Dealers Licence enables the Company to import/export, buy/sell, store, dispose of and trade all forms of cannabis, including dried flower and oils. The ACMPR requires mandatory quality control and product testing of all cannabis products destined for sale, with testing currently being conducted by Licensed Dealers. Anandia Labs is Canada’s leading independent cannabis analytics and genetics testing company, with approximately a 20% market share under the ACMPR. The Company operates out of a 5,400 square foot facility in Vancouver, British Columbia and has plans to construct a 40,000 square foot purpose-built cannabis innovation centre in British Columbia during 2018.
Anandia Labs is 19% owned by CannaRoyalty Corp., an active investor and operator in the legal cannabis industry and a Canadian publicly-traded company (CSE:CRZ) (OTCQX: CNNRF).
About Anandia Labs
Anandia Labs is a biotechnology company focused exclusively on cannabis, with the aim of bringing the best of modern science to the cannabis industry for the benefit of growers and consumers. Anandia Labs provides industry leading analytical testing services including potency, pesticides, microbes and terpenes to Licenced Producers and patients. In addition, Anandia Labs uses its cannabis-specific scientific expertise to assist its customers in the analysis of their testing results and resolution of any detected non-conformities.
Anandia Labs has also completed extensive research into cannabis genetics and has built a significant collection of cannabis germplasm. The Company uses modern plant breeding approaches to develop next generation cannabis varieties. Anandia Labs holds a Dealers Licence from Health Canada pursuant to the provisions of the Controlled Drugs and Substances Act and the Narcotic Control Regulations. The Dealers Licence permits Anandia Labs to analyze and extract cannabis, as well as cultivate cannabis for breeding and strain improvement.
For further information, please contact:
Jonathan Page, President and CEO
Lana Culley, Director of Business Development
Cautionary Statement on Forward-Looking Information
Certain information contained in this press release, including any information as to Anandia Laboratories Inc.’s (the “Corporation”) strategy, projects, plans or future financial or operating performance, constitutes "forward-looking statements". All statements, other than statements of historical fact, are forward-looking statements. The words "will", "expect", "continue", "assess", "positions" and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions; including material estimates and assumptions that, while considered reasonable by the Corporation as at the date of this press release in light of each of management's experience and perception of current conditions and expected developments, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements and undue reliance should not be placed on such statements and information. Any forward-looking statements included in this document are made as of the date of this document and the Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Although management of the Corporation believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct.